Exploring Regulated Bioanalysis For Small Molecules Bioanalysis 2020
Exploring Regulated Bioanalysis For Small Molecules Bioanalysis 2020 reveals several interesting facts.
- Patrick Faustino, CDER Office of Pharmaceutical Quality (OPQ), provides context for
- Tian Ma, CDER Office of Generic Drugs, summarize common reasons/codes of study sample reanalysis in pharmacokinetic (PK) ...
- Zhen Zhang, CDER Office of Generic Drugs, explains how to identify challenges in establishing bioequivalence (BE) of drug ...
- Waiting weeks for
- Dr. Ryan Chu, the Director of Chemistry at Emery Pharma, will be presenting a series of talks covering various aspects of ...
In-Depth Information on Regulated Bioanalysis For Small Molecules Bioanalysis 2020
Diaa Shakleya, CDER Office of Pharmaceutical Quality (OPQ), discusses Jinhui Zhang, CDER Office of Pharmaceutical Quality, discusses the Biologics Price Competition and Innovation Act (BPCI) Act ... The discussion begins with an introduction to Director of the Office of Translational Sciences (OTS) ShaAvhrée Buckman-Garner, MD, PhD, FAAP, opened the meeting ...
Ruben Ayala, CDER Office Translational Sciences, discusses
Stay tuned for more updates related to Regulated Bioanalysis For Small Molecules Bioanalysis 2020.